Section review oncologic, endocrine & metabolic: Novel lignans and their role in cancer chemotherapy

Expert Opinion on Therapeutic Patents

Volumn 6, Issue 6, 1996, Pages 547-554

  Middel, Oskar ^a  

^a NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0343157078     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.6.6.547     Document Type: Article

References (41)

1. AYRES DC, LOIKE JF: Lignans. In: Chemical, Biological and Clinical Properties (1990), Cambridge University Press.
2. FUJITA A, TAKABATAKE H, TAGAKI S, SERINE K: Pilot study of irinotecan in refractory small cell lung cancer. Can To Kagaku Ryoho (1995) 22:889-893 (Japanese).
3. GRANETZNY A, WINTER J, KANTARTZIS M, STEINBACH M, BORCHARD F, JUNIIBLUT MR, SCHULTE KD: Primary seminoma, a rare mediastinal tumour. Langenbecks Arch. Chir. (1995) 380:149-153 (German).
4. FRASCI G, COMELLA G, COMELLA P, CONFORTI S, MAS-TRANTONIO P, ZULLO F, PERSICO G: Carboplatin (CBDCA)-hexamethyJmelamine (HMM)-oral etoposide CVP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase n study. Gynaecol. Oncol. (1995) 58:68-83
5. MECHETNER EB: Multidrug resistance: progress analysis. Exp. Opin. Ther. Patents (1995) 5(6):535-542.
6. KUHN M, VON WARTBURG A: Liber ein neues Gby-cosidierungsverfahren. Synthase von epipodophyllo-toxin-beta-D-ghicopyranoside. Helv. Chim. Acta (1968) 51:1631-1636.
7. HARTMAN F, STAHELIN A, VON WARTBURG A: The chemi- cal and biological route from podophyllotoxin to etoposide: Ninth Cain Memorial Award lecture. Cancer Research (1991) 51:5-15.
8. ZHOU XM, LEE KJ, CHENG J, CHEN HX, GUO X, CHENG YC, LEE KH: Antitumour Agents, new gamma-lactone ring-modified arylamino etoposide analogues as inhibitors of human DNA topoisomerase-II. J. Med. Chem. (1994) 37(2):287-292.
9. ISHIHARA H, KAJIWARA K, OHSHITA N, KIURA Y, NISHISAKI T ITO H: IFN-beta inhibition of etoposide resistance acquisition in vitro: Studies using a human glioblastoma cell line. Anticancer Res. (1995) 15(2):283-287.
10. WHITE JC, MINES LH, RATIIMELLJP: Inhibition of 1-beta-D-arabinofuranosyl- cytosine transport and net accumulation by teniposide and etoposide in Ehrlich ascites cells and human leukemic blasts. Cancer Research (1985) 45:3070-3075.
11. BIAGLOW JE, VARNES ME, EPP ER, TUTTLE SW, HELD KD: Role of glutathione and other thiols in cellular res ponse to radiation and drugs. Drug Metab. Rev. (1989) 20:1-12.
12. MANS DRA, SCHUURHUIS GJ, TRESKES M, LAFLEUR MVM, RETEL J, PINEDO HM, LANKELMA J: Modulation by d,I-Buthionine-S,R-sulphoximine of etoposide cytotoxicity on human non small-cell lung, ovarian and breast carcinoma cell lines. Eur. J. Cancer (1992) 28A:1447-1452.
13. POST PE, SMIT EF, HAAXMA-REICHE H, VAN ZANDWIJK N, ARDIZZONI A, QUOIX E, SAHMOUD T, GIACCONE G: Teniposide for brain metastases of small-cell lung cancer: a phase II study. J. Clin. Oncol. (1995) 13(3):660-665.
14. SIMMONDS PD, MEAD G, WHITEHOUSE JM: A compll-cated case of metastatic teratoma. Growing teratoma syndrome and cerebral metastasis. Ann. Oncol. (1995) 6(2):181-185.
15. NEUWELT EA, WILLIAMS PC, MICKEY BE, FRENKEL EP, HENNER WD: Therapeutic dilemma of disseminated CNS germinoma and the potential of increased platinum-based chemotherapy delivery with osmotic blood-brain barrier disruption. Pediatr. Neurosurg. (1994) 21(l):l6-22.
16. TOMIOKA D, DUBOTA Y, KOGA K: Design, synthesis, and antitumour activity-absolute configuration relationships of podophyllotoxln aza-analogues. Tetrahedron (1993) 49:1891-1900.
17. ALUEVI P, ANASTASIA M, CIUFREDA P: Tetrahedron Lett. (1993) 34:7313-7316.
18. LAVELLE F, BISSERY MC, COMBEAU C, RIOU JF, VRIGNAUD P, ANDRE S: Preclinical evaluation of docetaxel (Taxotere). Semin-Oncol. (1995) 22(2 suppl. 4):3-l6.
19. McKEITHAN TW, ROSENBAU JL: CeU Muscle Motit. (1979) 5:225-228.
20. MIDDEL O, WOERDENBAG HJ, VAN UDEN W, VAN OEVEREN A, JANSEN JFGA, FERINGA BL, KONINGS AWT, KELLOGG RM: Synthesis and cytotoxicity of novel lig-nans. J Med. Chem. (1995) 38:2112-2118.
21. GORDALIZA M, CASTRO MA, GARCIA-GRAVALOS MD, RUIZ P, MIGUEL DEMYELINATED CORRAL JM, SAN FE-LICIANO A: Antineoplastic and antiviral activities of podophyllotoxin related lignans. Arch. Pharm. Weinheim (1994) 327(3):175-179.
22. VAN UDEN W, OEIJ II, WOERDENBAG HJ, PRAS N: Gluco-sylation of cyclodextrin-complexed podophyllotoxin by cell cultures of Linum flavum L. Plant Cell, Tissue and Organ Culture (1995) 34:169-175.
23. KUTNEY JP: Plant cell cultures and synthetic chemistry - a powerful route to complex natural products. P. Cell Cult. and Synth. Chem. (1991) 1:11-19
24. -24. ERMAN C, ADLERCREUTZ T, GOLDIN BR, GORBACH SL, HOCKERSTEDT KA, WATANABE S, HAMALAINEN EK, MARKKANEN MH, MAKELA TH, WAHALA KT et al: Soybean phytoestrogen intake and cancer risk. J. Nutr. (1995) 125(3):757S-770S.
25. WANG C, MAKELA T, HASE T, ADLERCRUTZ II, KURZER MS: Lignans and flavanoids inhibit aromatase enzyme in human preadipocytes. J. Steroid Biochem. Mol. Biol. (1994) 50(3-4) 205-212.
26. PIERRE FABRE MEDICAMENT, W09414829-A (1994).
27. TEVA PHARM. IND. LTD., US5463040-A (1995).
28. BRISTOL-MYERS SQUIBB CO., EP-652226-A (1995).
29. BRISTOL-MYERS SQUIBB CO., EP-537555-A (1993).
30. BRISTOL-MYERS SQUIBB CO., EP-548834-A (1993).
31. MATRIX PHARM. INC., WO9517901-A (1995).
32. ST. JUDE CHILDREN'S RES. HOSPITAL, US5371081-A (1995)
33. TAKARA SHUZO et al, JP7233084-A (1995).
34. RHONE-POULENC RORER SA, WO9410995-A (1994).
35. BRISTOL-MYERS SQUIBB CO., EP-645145-A (1995).
36. UNIVERSITY OF ILLINOIS, WO9420618-A (1994).
37. MADAUSAG,EP-667154-A(1995).
38. UNIVERSITY OF MIAMI, US5486509-A (1996).
39. TSUMURA & CO., EP-532328-A (1993).
40. TAIHO YAKUHIN KOGYO KK, et al, JP7053553-A (1995).
41. NEW ENGLAND DEACONESS HOSPITAL CORP., W09522971-A (1995).